#OP0237 reports positive phase 3 data for the selective JAK1 inhibitor ivarmacitinib in active nr-axSpA. ASAS40 responses at Week 12 significantly higher vs placebo (39.7% vs 24.8%), with sustained efficacy through Week 24 and no new safety signals observed. #EULAR2026 @RheumNow https://t.co/JZLQ0Ywlio

Prof. Wittmann discusses the current tx for CLE using a stepwise approach. Smoking is a challenge in D2T skin #lupus due to data showing that smoking reduces efficacy of antimalarials & worsens dse act & damage. Advocate for smoking cessation! @Rheumnow #EULAR2026 https://t.co/pEWLJAkBAJ

Evidence on diet changing prognosis or incidence of rheumatic diseases is limited. However overall need to encourage health diets. Plenary at #EULAR2026 @RheumNow Summary below. https://t.co/QC0Li38eh6

#EULAR2026 POS0729 Longer-term data of autologous CD19 CAR-T appear favourable in #SLE. 4-year data of the initial 8 patients treated at Erlangen remained in GC- and IS-free remission. Infection profile declined over time apart from some blips during COVID pandemic @RheumNow https://t.co/QZMxA2CK33

Catching up with the “Optimising care in SpA” at #EULAR2026 #OP0234 Phase 3 OLINGUITO trial showed filgotinib significantly improved ASAS40 responses vs PBO in both radiographic and non-radiographic axSpA by Week 16, with responses maintained through Week 52. @RheumNow #EULARBest https://t.co/axn6Zv52RA

#EULAR2026 OP022 We need to think beyond proteinuria to assess activity & response in #lupusnephritis. ReBioLup study showed 67% of patients with persistent histologic activity at 12 months (NIH=>4) still met criteria for complete clinical response @RheumNow https://t.co/bRFNrNLjJX

#EULAR2026 OP0170 Progress of CAR-T in myositis? Phase 1 of rese-cel autologous CD19 CAR-T (advantage: humanised, 4-1BB Co-stimulatory Domain to enhance cells expansion) showed no safety signals and early efficacy in 4 IIM subtypes. Both anti-synthetase pts relapsed @RheumNow https://t.co/QisldedCti

What to use in #RA #IL6i v #abatacept post #TNFi-IR? H2H #TCZ v #Abatacept Same on primary outcome #CDAI change wk26 BUT If #monoRx TCZ better Better retention #TCZ So you decide which is better! Equal v some advantages w #tocilizumab #EULAR2026 @RheumNow @eular_org #OP0205 https://t.co/xdOx4kQCTC

Leflunomide is not associated w/ incident or progressive ILD Longitudinal CT Study 184 RA pts LEF exposure inversely asso w/ new lung involvement #POS062 #EULAR2026 @RheumNow https://t.co/LBrfycalLf

Brand new #MOA in #Rx of #skin #lupus! #Litifilimab - acts on #dendritic cells ⬇️decreases #chemokines & #cytokines +RCT in #cutaneous features of lupus N=93 2:1 randomized #liti v #pbo Rapid onset <4wks HIgh #CLASI response #EULARbest #EULAR226 @RheumNow @eular_org POS438 https://t.co/TXqggO1jCU

SCOOT study oral split-dose vs SC MTX RA Primary outcome EULAR mod/good response wk16 Non-inferiority NOT met EULAR good response lower with oral split-dose OR 0.53 ACR50 lower with oral split-dose OR 0.51 Safety oral split-dose Higher transaminitis (>2× ULN) 3 serious AEs https://t.co/c8etFKtGwo